Gene Transfer and the Treatment of Childhood Cancer

References

• Anderson W F. The ADA human gene therapy clinical protocol. Hum Gene Ther 1990; 1: 327–362
   PubMed Web of Science ®Google Scholar
• Brenner M K, Rill D R, Moen R C, et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85–86
   PubMed Web of Science ®Google Scholar
• Brenner M K, Rill D R, Holladay M S, et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 1993; 342: 1134–1137
   PubMed Web of Science ®Google Scholar
• Rosenberg S A. Gene therapy for cancer. JAMA 1992; 268: 2416–2419
   PubMed Web of Science ®Google Scholar
• Engelhardt J F, Yang Y, Stratford-Perricaudet L D, et al. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nature Genetics 1993; 4: 27–34
   PubMed Web of Science ®Google Scholar
• Le Gal La Salle G, Robert J J, Berrard S, et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 1993; 259: 988–990
   PubMed Web of Science ®Google Scholar
• Fisher K J, Jooss K, Alstron J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nature Medicine 1997; 3: 306–312
   PubMed Web of Science ®Google Scholar
• Nabel G J, Nabel E G, Yang Z Y, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90(23)11307–11311
   PubMed Web of Science ®Google Scholar
• Gao X, Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 1991; 179: 280–285
   PubMed Web of Science ®Google Scholar
• Trubetskoy V S, Torchilin V P, Kennel S J, et al. Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly-L-lysine-antibody conjugate in mouse lung endothelial cells. Biochim Biophys Acta 1992; 1131: 311–313
   PubMed Web of Science ®Google Scholar
• Brenner M K. The applications of gene transfer of pediatric malignant disease. Principles and Practice of Pediatric Oncology, 3rd ed., P A Pizzo, D G Poplack. JB Lippincott, Philadelphia 1997; 375–384
   Google Scholar
• Miller A D. Human gene therapy comes of age. Nature 1992; 357: 455–460
   PubMed Web of Science ®Google Scholar
• Dilloo D, Rill D, Entwistle C, et al. A novel herpes vector for the high efficiency transduction of normal and malignant human hemopoietic cells. Blood 1997; 89: 119–127
   PubMed Web of Science ®Google Scholar
• Snyder D S, Wu Y, Wang J L, et al. Ribozyme-mediated inhibition of bcr-abl gene expression in Philadelphia chromosome-positive cell line. Blood 1993; 82: 600–605
   PubMed Web of Science ®Google Scholar
• Scanlon K J, Jiao L, Funato T, et al. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA 1991; 88: 10591–10595
   PubMed Web of Science ®Google Scholar
• Ratajczak M Z, Kant J A, Luger S M, et al. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 1992; 89: 11823–11827
   PubMed Web of Science ®Google Scholar
• Kijima H, et al. Therapeutic application of ribozymes. Pharmacol Ther 1995; 68: 247–267
   PubMed Web of Science ®Google Scholar
• Roth J A, Nguyen D, Lawrence D D, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Medicine 1996; 2: 985–991
   PubMed Web of Science ®Google Scholar
• Rossi J J. Therapeutic antisense and ribozymes. Br Med Bull 1995; 51: 217–225
   PubMed Web of Science ®Google Scholar
• Zhang Y, Mukhopadhyay T, Donehower L A, et al. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 1993; 4: 451–460
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Grimm E A, Cai D W, et al. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993; 53: 4129–4133
   PubMed Web of Science ®Google Scholar
• Wang J, Bucana C D, Roth J A, et al. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther 1995; 2: 9–18
   PubMed Web of Science ®Google Scholar
• Culver K W, Ram Z, Wallbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550–1552
   PubMed Web of Science ®Google Scholar
• Ram Z, Culver K W, Walbridge S, et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993; 83–88
   PubMed Web of Science ®Google Scholar
• Bi W L, Parysek L M, Wamick R, et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993; 4: 725–732
   PubMed Web of Science ®Google Scholar
• Freeman S M, Abboud C N, Whartenby K A, et al. The “bystander effect”: Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274–5283
   PubMed Web of Science ®Google Scholar
• Huber B E, Austin E A, Richards C A, et al. Metabolism of 5-fluo-rocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994; 91: 8302–8806
   PubMed Web of Science ®Google Scholar
• Mullen C A, Coale M M, Lowe R, et al. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 1994; 54: 1503–1506
   PubMed Web of Science ®Google Scholar
• Wei M X, Tamiya T, Chase M, et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 1994; 5: 969–978
   PubMed Web of Science ®Google Scholar
• Knox R J, Friedlos F, Boland M P. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metas Rev 1993; 12: 195–212
   PubMed Web of Science ®Google Scholar
• Mroz P J, Moolten F L. Retrovirally transduced Escherichia coli gpt genes combine selectability with chemosensitivity capable of mediating tumor eradication. Hum Gene Ther 1993; 4: 589–595
   PubMed Web of Science ®Google Scholar
• Sorscher E J, Peng S, Bebok Z, et al. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther 1994; 1: 233–238
   PubMed Web of Science ®Google Scholar
• Huber B E, Richards C A, Austin E A. Virus-directed enzyme/prodrug therapy (VDEPT). Selectively engineering drug sensitivity into tumors. Ann NY Acad Sci 1994; 716: 104–114
   PubMed Web of Science ®Google Scholar
• Bischoff J R, Kirn D H, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373–376
   PubMed Web of Science ®Google Scholar
• Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nature Medicine 1996; 2: 1090–1095
   PubMed Web of Science ®Google Scholar
• Tahara H, Lotze M T. Gene therapy for adult cancers: Advances in immunologic approaches using cytokines. Somatic Gene Therapy, P L Chang. CRC Press, Ann Arbor, MI 1994; 15: 263–286
   Google Scholar
• Chen L, Ashe S, Brady W A, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093–1102
   PubMed Web of Science ®Google Scholar
• Townsend S E, Allison J P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993; 259: 368–370
   PubMed Web of Science ®Google Scholar
• Tepper R I, Pattengale P K, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503–512
   PubMed Web of Science ®Google Scholar
• Golumbek P T, Lazenby A J, Levitsky H I, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254: 713–716
   PubMed Web of Science ®Google Scholar
• Fearon E R, Pardoe D M, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397–403
   PubMed Web of Science ®Google Scholar
• Gansbacher B, Zier K, Daniels B, et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217–1224
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539
   PubMed Web of Science ®Google Scholar
• Colombo M P, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991; 173: 889–897
   PubMed Web of Science ®Google Scholar
• Colombo M P, Fomi G. Cytokine gene transfer in tumor inhibition and tumor therapy: Where are we now?. Immunol Today 1994; 15: 48–51
   PubMedGoogle Scholar
• Hock H, Dorsch M, Kunzendorf U, et al. Vaccinations with tumor cells genetically engineered to produce different cytokines: Effectivity not superior to a classical adjuvant. Cancer Res 1993; 53: 714–716
   PubMed Web of Science ®Google Scholar
• Yamada G, Kitamura Y, Sonoda H, et al. Retroviral expression of the human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity. EMBO J 1993; 6: 2705–2709
   Google Scholar
• Lapidot T, Sirard C, Voroor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645–648
   PubMed Web of Science ®Google Scholar
• Horowitz M M, Gale R P, Sondel P M, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Papadopoulos E B, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185–1191
   PubMed Web of Science ®Google Scholar
• Brenner M K, Heslop H E. Graft-versus-host reactions and bone marrow transplantation. Curr Opin Immunol 1991; 3: 752–757
   PubMed Web of Science ®Google Scholar
• Melief C J, Kast W M. Potential immunogenicity of oncogene and tumor suppressor gene products. Curr Opin Immunol 1993; 5: 709–713
   PubMed Web of Science ®Google Scholar
• Rooney C M, Smith C A, Ng C, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995; 345: 9–13
   PubMed Web of Science ®Google Scholar
• Van Der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643–1647
   PubMed Web of Science ®Google Scholar
• Straus S E, Cohen J I, Tosato G, et al. Epstein-Barr virus infections: Biology, pathogenesis and management. Ann Intern Med 1992; 118: 45–58
   Web of Science ®Google Scholar
• Heslop H E, Ng C YC, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Medicine 1996; 2: 551–555
   PubMed Web of Science ®Google Scholar
• Doherty P C. Cell-mediated cytotoxicity. Cell 1993; 75: 607–612
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A. Identifying strategies for immune intervention. Science 1993; 260: 937–944
   PubMed Web of Science ®Google Scholar
• Murphy D, Crowther D, Renninson J, et al. A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Ann Oncol 1993; 4: 377
   PubMed Web of Science ®Google Scholar
• Levin L, Hryniuk W M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756
   PubMed Web of Science ®Google Scholar
• Levin L, Simon R, Hryniuk W. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer Inst 1993; 85: 1732
   PubMed Web of Science ®Google Scholar
• Pastan I, Gottesman M M. Multidrug resistance. Annu Rev Med 1991; 42: 277
   PubMed Web of Science ®Google Scholar
• Mickisch G H, Licht T, Merlino G T, et al. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Cancer Res 1991; 51: 5417
   PubMed Web of Science ®Google Scholar
• Mickisch G H, Merlino G T, Galski H, et al. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 1991; 88: 547
   PubMed Web of Science ®Google Scholar
• McLachlin J R, Eglitis M A, Ueda K, et al. Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer. J Natl Cancer Inst 1990; 82: 1260
   PubMed Web of Science ®Google Scholar
• Moritz T, Mackay W, Feng L J, et al. Gene transfer of 06-methyl-guanine methyltransferase (MGMT) protects hematopoietic cells (HC) from nitrosourea (NU) induced toxicity in vitro and in vivo. Blood 1993; 82(Suppl 1)118a, (abstract)
   PubMedGoogle Scholar
• Appelbaum F R, Buckner C D. Overview of the clinical relevance of autologous bone marrow transplantation. Clin Haematol 1986; 15: 1–18
   PubMedGoogle Scholar
• Burnett A K, Tansey P, Watkins R, et al. Transplantation of unpurged autologous bone-marrow in acute myeloid leukaemia in first remission. Lancet 1984; 2: 1068–1070
   PubMed Web of Science ®Google Scholar
• Goldstone A H, Anderson C C, Linch D C, et al. Autologous bone marrow transplantation following high dose chemotherapy for the treatment of adult patients with acute myeloid leukaemia. Br J Haematol 1986; 64: 529–537
   PubMed Web of Science ®Google Scholar
• Brugger W, Bross K J, Glatt M, et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636–640
   PubMed Web of Science ®Google Scholar
• Shpall E J, Jones R B. Release of tumor cells from bone marrow. Blood 1994; 83: 623–625
   PubMed Web of Science ®Google Scholar
• Rill D R, Santana V M, Roberts W M, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84: 380–383
   PubMed Web of Science ®Google Scholar
• De Fabritiis P, Ferrero D, Sandrelli A, et al. Monoclonal antibody purging and autologous bone marrow transplantation in acute myelogenous leukemia in complete remission. Bone Marrow Transplant 1989; 4: 669–674
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Rivoltini L, Fizzotti M, et al. Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells. Br J Haematol 1991; 78: 197–205
   PubMed Web of Science ®Google Scholar
• Gorin N C, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging. Blood 1990; 75(75)1606–1614
   PubMedGoogle Scholar
• Santos G W, Yeager A M, Jones R J. Autologous bone marrow transplantation. Annu Rev Med 1989; 40: 99–112
   PubMed Web of Science ®Google Scholar
• Gribben J G, Freedman A S, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525–1533
   PubMed Web of Science ®Google Scholar
• Petersen F B, Buckner C D. Allogeneic and autologous bone marrow transplantation for acute leukemia and malignant lymphoma: current status. Hematol Oncol 1987; 5: 233–243
   PubMed Web of Science ®Google Scholar
• Yeager A M, Kaizer H, Santos G W, et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxy-cyclophosphamide. N Engl J Med 1986; 315: 141–147
   PubMed Web of Science ®Google Scholar
• Deisseroth A B, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068–3076
   PubMed Web of Science ®Google Scholar
• Dunbar C E, Bodine D M, Sorrentino B, et al. Gene transfer into hematopoietic cells: Implications for cancer therapy. Ann NY Acad Sci 1994; 716: 216–224
   PubMed Web of Science ®Google Scholar
• Riddell S R, Elliot M, Lewinsohn D A, et al. T-cell mediated rejection of gene-modified HTV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Medicine 1996; 2: 216–223
   PubMed Web of Science ®Google Scholar